308 related articles for article (PubMed ID: 23696960)
21. Targeted Therapies for Lung Cancer.
Stinchcombe TE
Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
[TBL] [Abstract][Full Text] [Related]
22. Targeted Therapy for NSCLC--A Double-edged Sword?
Dempke WC
Anticancer Res; 2015 May; 35(5):2503-12. PubMed ID: 25964523
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
24. Extending survival of stage IV non-small cell lung cancer.
Carnio S; Novello S; Mele T; Levra MG; Scagliotti GV
Semin Oncol; 2014 Feb; 41(1):69-92. PubMed ID: 24565582
[TBL] [Abstract][Full Text] [Related]
25. Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.
Kuykendall A; Chiappori A
Cancer Control; 2014 Jan; 21(1):67-73. PubMed ID: 24357744
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.
Tazza M; Metro G
J Thorac Dis; 2017 Oct; 9(10):4064-4069. PubMed ID: 29268417
[TBL] [Abstract][Full Text] [Related]
27. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y; Chen G; Chen J; Zhuang L; Du Y; Yu Q; Zhuang W; Zhao Y; Zhou M; Zhang W; Zhang Y; Wan Y; Li W; Song W; Wang ZM; Li B; Xia M; Yang Y; Fang W; Huang Y; Zhang L
EClinicalMedicine; 2023 Aug; 62():102106. PubMed ID: 37593227
[TBL] [Abstract][Full Text] [Related]
28. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.
Connock M; Armoiry X; Tsertsvadze A; Melendez-Torres GJ; Royle P; Andronis L; Clarke A
BMC Cancer; 2019 Apr; 19(1):392. PubMed ID: 31023244
[TBL] [Abstract][Full Text] [Related]
29. Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.
Hayashi H; Nishio M; Takahashi M; Tsuchiya H; Kasahara-Kiritani M
Adv Ther; 2023 Oct; 40(10):4545-4560. PubMed ID: 37572265
[TBL] [Abstract][Full Text] [Related]
30. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Perdrizet K; Leighl NB
Curr Treat Options Oncol; 2019 Feb; 20(3):21. PubMed ID: 30778772
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
32. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
33. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives.
Pakkala S; Ramalingam SS
Curr Opin Oncol; 2016 Mar; 28(2):150-8. PubMed ID: 26809014
[TBL] [Abstract][Full Text] [Related]
35. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
36. Metastatic Lung Cancer: Emerging Therapeutic Strategies.
Saif Ur Rehman S; Ramalingam SS
Semin Respir Crit Care Med; 2016 Oct; 37(5):736-749. PubMed ID: 27732995
[TBL] [Abstract][Full Text] [Related]
37. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R
Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239
[TBL] [Abstract][Full Text] [Related]
38. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.
Giustini NP; Jeong AR; Buturla J; Bazhenova L
Clin Chest Med; 2020 Jun; 41(2):223-235. PubMed ID: 32402358
[TBL] [Abstract][Full Text] [Related]
39. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
[TBL] [Abstract][Full Text] [Related]
40. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
